<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACCUPRIL- quinapril hydrochloride tablet, film coated </strong><br>Cardinal Health<br></p></div>
<h1>Accupril®<br>(Quinapril Hydrochloride Tablets)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_246c6147-c9ed-426e-9b93-bcb0f3236b1b"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">USE IN PREGNANCY</span></p>
<p><span class="Bold">When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span> When pregnancy is detected, ACCUPRIL should be discontinued as soon as possible. See <a href="#i4i_section_id_e2e3f683-87f4-4d30-929a-047e14a063b2">WARNINGS, Fetal/Neonatal Morbidity and Mortality</a>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_9230e303-9b08-44e6-8ebe-638600661d80"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ACCUPRIL® (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat.</p>
<p>Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C<span class="Sub">25</span>H<span class="Sub">30</span>N<span class="Sub">2</span>O<span class="Sub">5</span>•HCl and its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a2de05b9-d1aa-4fbb-a9a3-6918cc306f78&amp;name=b342078c-2f2f-4f66-82bd-1ac0c095fbc1-01.jpg"></div>
<p>Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents.</p>
<p>ACCUPRIL tablets contain 5 mg, 10 mg, 20 mg, or 40 mg of quinapril for oral administration. Each tablet also contains candelilla wax, crospovidone, gelatin, lactose, magnesium carbonate, magnesium stearate, synthetic red iron oxide, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_29795514-83f9-4837-85b6-b6c7d5ad3ffc"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad4945f2-bccd-4578-9bf1-8aee5318e542"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation. Quinapril inhibits the elevation in blood pressure caused by intravenously administered angiotensin I, but has no effect on the pressor response to angiotensin II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption. Reduced aldosterone secretion by quinapril may result in a small increase in serum potassium. In controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> trials, treatment with ACCUPRIL alone resulted in mean increases in potassium of 0.07 mmol/L (see <a href="#i4i_precautions_id_0c8a7a5f-0d8b-4ab1-ab07-edc8c713a65d">PRECAUTIONS</a>). Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity (PRA).</p>
<p>While the principal mechanism of antihypertensive effect is thought to be through the renin-angiotensin-aldosterone system, quinapril exerts antihypertensive actions even in patients with low renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACCUPRIL was an effective antihypertensive in all races studied, although it was somewhat less effective in blacks (usually a predominantly low renin group) than in nonblacks. ACE is identical to kininase II, an enzyme that degrades bradykinin, a potent peptide vasodilator; whether increased levels of bradykinin play a role in the therapeutic effect of quinapril remains to be elucidated.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_14d0b001-0b2a-4dd9-bb8f-c6ae090792d0"></a><a name="section-2.1.1"></a><p></p>
<h3>Pharmacokinetics and Metabolism</h3>
<p class="First">Following oral administration, peak plasma quinapril concentrations are observed within one hour. Based on recovery of quinapril and its metabolites in urine, the extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25–30%) when ACCUPRIL tablets are administered during a high-fat meal. Following absorption, quinapril is deesterified to its major active metabolite, quinaprilat (about 38% of oral dose), and to other minor inactive metabolites. Following multiple oral dosing of ACCUPRIL, there is an effective accumulation half-life of quinaprilat of approximately 3 hours, and peak plasma quinaprilat concentrations are observed approximately 2 hours post-dose. Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose, and has an elimination half-life in plasma of approximately 2 hours and a prolonged terminal phase with a half-life of 25 hours. The pharmacokinetics of quinapril and quinaprilat are linear over a single-dose range of 5–80 mg doses and 40–160 mg in multiple daily doses. Approximately 97% of either quinapril or quinaprilat circulating in plasma is bound to proteins.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, the elimination half-life of quinaprilat increases as creatinine clearance decreases. There is a linear correlation between plasma quinaprilat clearance and creatinine clearance. In patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, chronic hemodialysis or continuous ambulatory peritoneal dialysis has little effect on the elimination of quinapril and quinaprilat. Elimination of quinaprilat may be reduced in elderly patients (≥65 years) and in those with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>; this reduction is attributable to decrease in renal function (see <a href="#i4i_dosage_admin_id_520203ca-c42b-4bff-a36c-e84bd7a7d080">DOSAGE AND ADMINISTRATION</a>). Quinaprilat concentrations are reduced in patients with <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> due to impaired deesterification of quinapril. Studies in rats indicate that quinapril and its metabolites do not cross the blood-brain barrier.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca3c9317-3383-4a15-9385-2bf565c52a9c"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacodynamics and Clinical Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdc8cc46-b50f-4c8d-9ea0-931ba219c15e"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h3>
<p class="First">Single doses of 20 mg of ACCUPRIL provide over 80% inhibition of plasma ACE for 24 hours. Inhibition of the pressor response to angiotensin I is shorter-lived, with a 20 mg dose giving 75% inhibition for about 4 hours, 50% inhibition for about 8 hours, and 20% inhibition at 24 hours. With chronic dosing, however, there is substantial inhibition of angiotensin II levels at 24 hours by doses of 20–80 mg.</p>
<p>Administration of 10 to 80 mg of ACCUPRIL to patients with mild to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> results in a reduction of sitting and standing blood pressure to about the same extent with minimal effect on heart rate. Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> is infrequent although it can occur in patients who are salt-and/or volume-depleted (see <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>). Antihypertensive activity commences within 1 hour with peak effects usually achieved by 2 to 4 hours after dosing. During chronic therapy, most of the blood pressure lowering effect of a given dose is obtained in 1–2 weeks. In multiple-dose studies, 10–80 mg per day in single or divided doses lowered systolic and diastolic blood pressure throughout the dosing interval, with a trough effect of about 5–11/3–7 mm Hg. The trough effect represents about 50% of the peak effect. While the dose-response relationship is relatively flat, doses of 40–80 mg were somewhat more effective at trough than 10–20 mg, and twice daily dosing tended to give a somewhat lower trough blood pressure than once daily dosing with the same total dose. The antihypertensive effect of ACCUPRIL continues during long-term therapy, with no evidence of loss of effectiveness.</p>
<p>Hemodynamic assessments in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> indicate that blood pressure reduction produced by quinapril is accompanied by a reduction in total peripheral resistance and renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> with little or no change in heart rate, <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span>, renal blood flow, glomerular filtration rate, or filtration fraction.</p>
<p>Use of ACCUPRIL with a thiazide diuretic gives a blood-pressure lowering effect greater than that seen with either agent alone.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, ACCUPRIL 10–40 mg was similar in effectiveness to captopril, enalapril, propranolol, and thiazide diuretics.</p>
<p>Therapeutic effects appear to be the same for elderly (≥65 years of age) and younger adult patients given the same daily dosages, with no increase in adverse events in elderly patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee4edf0b-983f-4a19-9d5f-14309e51aa18"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h3>
<p class="First">In a placebo-controlled trial involving patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> treated with digitalis and diuretics, parenteral quinaprilat, the active metabolite of quinapril, reduced pulmonary capillary wedge pressure and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and increased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>/index. Similar favorable hemodynamic effects were seen with oral quinapril in baseline-controlled trials, and such effects appeared to be maintained during chronic oral quinapril therapy. Quinapril reduced renal hepatic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and increased renal and hepatic blood flow with glomerular filtration rate remaining unchanged.</p>
<p>A significant dose response relationship for improvement in maximal exercise tolerance has been observed with ACCUPRIL therapy. Beneficial effects on the severity of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> as measured by New York Heart Association (NYHA) classification and Quality of Life and on symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> were evident after 6 months in a double-blind, placebo-controlled study. Favorable effects were maintained for up to two years of open label therapy. The effects of quinapril on long-term mortality in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have not been evaluated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_dca2b292-4eeb-4586-8a13-204b958065ea"></a><a name="section-2.3"></a><p></p>
<h2>INDICATIONS AND USAGE</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_62c1bfc2-1614-462d-b5c9-b7ff03664937"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h3>
<p class="First">ACCUPRIL is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or in combination with thiazide diuretics<span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2519607-f5f1-4c63-97fa-4766a7b213ed"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h3>
<p class="First">ACCUPRIL is indicated in the management of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis.</p>
<p>In using ACCUPRIL, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or collagen vascular disease. Available data are insufficient to show that ACCUPRIL does not have a similar risk (see <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b49fd2d-b8a7-4c2f-93e5-ed23516e110d"></a><a name="section-2.3.2.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> in black patients</h4>
<p class="First">Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_2a019b79-d7ee-4495-8ae0-2ce8e5bc0331"></a><a name="section-3"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ACCUPRIL is contraindicated in patients who are hypersensitive to this product and in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> related to previous treatment with an ACE inhibitor.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813"></a><a name="section-4"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_535a900f-50ec-4071-86fa-354541c6906c"></a><a name="section-4.1"></a><p></p>
<h2>Anaphylactoid and Possibly Related Reactions</h2>
<p class="First">Presumably because angiotensin-converting inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including <span class="Bold">ACCUPRIL</span>) may be subject to a variety of adverse reactions, some of them serious.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d65bade8-227c-4498-8d04-2377709d7e89"></a><a name="section-4.1.1"></a><p></p>
<h3>Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, extremities, lips, tongue, glottis, and larynx has been reported in patients treated with ACE inhibitors and has been seen in 0.1% of patients receiving ACCUPRIL.</p>
<p>In two similarly sized U.S. postmarketing trials that, combined, enrolled over 3,000 black patients and over 19,000 non-blacks, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was reported in 0.30% and 0.55% of blacks (in study 1 and 2 respectively) and 0.39% and 0.17% of non-blacks.</p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> can be fatal. If laryngeal <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of the face, tongue, or glottis occurs, treatment with ACCUPRIL should be discontinued immediately, the patient treated in accordance with accepted medical care, and carefully observed until the <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> disappears. In instances where <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> is confined to the face and lips, the condition generally resolves without treatment; antihistamines may be useful in relieving symptoms. <span class="Bold">Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, emergency therapy including, but not limited to, subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) should be promptly administered</span> (see <a href="#i4i_adverse_effects_id_60c22dfc-2d47-4413-affc-028600ab10bb">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9eb1a493-5e72-4ea4-902a-c1413f3add79"></a><a name="section-4.1.2"></a><p></p>
<h3>Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h3>
<p class="First">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been reported in patients treated with ACE inhibitors. These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal. The <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> should be included in the differential diagnosis of patients on ACE inhibitors presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f42ffef8-4302-4b05-bc50-4aae9e6e81bd"></a><a name="section-4.1.3"></a><p></p>
<h3>Patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></h3>
<p class="First">Patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> unrelated to ACE inhibitor therapy may be at increased risk of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> while receiving an ACE inhibitor (see also <a href="#i4i_contraindications_id_2a019b79-d7ee-4495-8ae0-2ce8e5bc0331">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1b29dc2f-6e39-4950-b294-7aa8d67f7108"></a><a name="section-4.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during desensitization</h3>
<p class="First">Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d64af84e-25fb-4f00-9cb7-a831a293144f"></a><a name="section-4.1.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during membrane exposure</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cfb59c1b-cb02-477c-852c-2c201a71da40"></a><a name="section-4.1.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></h3>
<p class="First">Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and (sometimes) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5d1a0b9-5d0e-442e-9f16-0ba1058a39ab"></a><a name="section-4.1.7"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h3>
<p class="First">Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is rare in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with ACCUPRIL alone. Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> given ACCUPRIL commonly have some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually is not necessary when dosing instructions are followed. Caution should be observed when initiating therapy in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (see <a href="#i4i_dosage_admin_id_520203ca-c42b-4bff-a36c-e84bd7a7d080">DOSAGE AND ADMINISTRATION</a>). In controlled studies, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was observed in 0.4% of patients (N=3203); this incidence was similar to that observed for captopril (1%) and enalapril (0.8%).</p>
<p>Patients at risk of excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, sometimes associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rarely with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, include patients with the following conditions or characteristics: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, high dose diuretic therapy, recent intensive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or increase in diuretic dose, renal dialysis, or severe volume and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> of any etiology. It may be advisable to eliminate the diuretic (except in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), reduce the diuretic dose or cautiously increase salt intake (except in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>) before initiating therapy with ACCUPRIL in patients at risk for excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> who are able to tolerate such adjustments.</p>
<p>In patients at risk of excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, therapy with ACCUPRIL should be started under close medical supervision. Such patients should be followed closely for the first two weeks of treatment and whenever the dose of ACCUPRIL and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease in whom an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> could result in a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>If excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of ACCUPRIL, which usually can be given without difficulty once the blood pressure has stabilized. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> develops, a dose reduction or discontinuation of ACCUPRIL or concomitant diuretic may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39dd15c3-42e9-4039-aff2-4bf971e54880"></a><a name="section-4.1.8"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h3>
<p class="First">Another ACE inhibitor, captopril, has been shown to cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> rarely in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span>, but more frequently in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, especially if they also have a collagen vascular disease, such as <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> or <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> did occur during ACCUPRIL treatment in one patient with a history of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> during previous captopril therapy. Available data from clinical trials of ACCUPRIL are insufficient to show that, in patients without prior reactions to other ACE inhibitors, ACCUPRIL does not cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> at similar rates. As with other ACE inhibitors, periodic monitoring of white blood cell counts in patients with collagen vascular disease and/or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2e3f683-87f4-4d30-929a-047e14a063b2"></a><a name="section-4.1.9"></a><p></p>
<h3>Fetal/Neonatal Morbidity and Mortality</h3>
<p class="First">ACE inhibitors can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.</p>
<p>The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> has also been reported, presumably resulting from decreased fetal renal function; <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> in this setting has been associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> have also been reported, although it is not clear whether these occurrences were due to the ACE inhibitor exposure.</p>
<p>These adverse effects do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of ACCUPRIL as soon as possible.</p>
<p>Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intraamniotic environment.</p>
<p>If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, ACCUPRIL should be discontinued unless it is considered life-saving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of <span class="Italics">in utero</span> exposure to ACE inhibitors should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. Removal of ACCUPRIL, which crosses the placenta, from the neonatal circulation is not significantly accelerated by these means.</p>
<p>No teratogenic effects of ACCUPRIL were seen in studies of pregnant rats and rabbits. On a mg/kg basis, the doses used were up to 180 times (in rats) and one time (in rabbits) the maximum recommended human dose.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_0c8a7a5f-0d8b-4ab1-ab07-edc8c713a65d"></a><a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_f5a4b539-20c2-4e32-8050-8dc6c440a3a0"></a><a name="section-5.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bfabaac-c62e-48d2-8ab8-434992002116"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></h3>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including ACCUPRIL, may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and rarely <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>In clinical studies in hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in blood urea nitrogen and serum creatinine have been observed in some patients following ACE inhibitor therapy. These increases were almost always reversible upon discontinuation of the ACE inhibitor and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy.</p>
<p>Some patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with no apparent preexisting renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when ACCUPRIL has been given concomitantly with a diuretic. This is more likely to occur in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction and/or discontinuation of any diuretic and/or ACCUPRIL may be required.</p>
<p><span class="Bold">Evaluation of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should always include assessment of renal function</span> (see <a href="#i4i_dosage_admin_id_520203ca-c42b-4bff-a36c-e84bd7a7d080">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92a5e048-0750-4be8-b3e4-58deedb49685"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> and potassium-sparing diuretics</h3>
<p class="First">In clinical trials, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium ≥5.8 mmol/L) occurred in approximately 2% of patients receiving ACCUPRIL. In most cases, elevated serum potassium levels were isolated values which resolved despite continued therapy. Less than 0.1% of patients discontinued therapy due to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with ACCUPRIL (see <a href="#i4i_interactions_id_61957d1f-4528-4cd8-b970-69fb6860c06f">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24da3877-24b8-4635-988f-076bfd82f17c"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></h3>
<p class="First">Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent non-<span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span> has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be considered in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d9a1f2c-2ebe-4b59-b01e-394e163c194d"></a><a name="section-5.1.4"></a><p></p>
<h3>Surgery/anesthesia</h3>
<p class="First">In patients undergoing major surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, ACCUPRIL will block angiotensin II formation secondary to compensatory renin release. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_68339b7f-d4e1-409b-a136-c3a98c64241b"></a><a name="section-5.2"></a><p></p>
<h2>Information for Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0dc3ca2c-fec3-4013-bcb0-0240d94d26c1"></a><a name="section-5.2.1"></a><p></p>
<h3>Pregnancy</h3>
<p class="First">Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fea0f1f6-7dad-4b75-8314-748d06f980c5"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> can occur with treatment with ACE inhibitors, especially following the first dose. Patients should be so advised and told to report immediately any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to stop taking the drug until they have consulted with their physician (see <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1976c9e4-dd51-49b4-8f1d-6a6b8ad435bf"></a><a name="section-5.2.3"></a><p></p>
<h3>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></h3>
<p class="First">Patients should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first few days of ACCUPRIL therapy, and that it should be reported to a physician. If actual <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, patients should be told to not take the drug until they have consulted with their physician (see <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>).</p>
<p>All patients should be cautioned that inadequate fluid intake or excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> because of reduction in fluid volume, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p>Patients planning to undergo any surgery and/or anesthesia should be told to inform their physician that they are taking an ACE inhibitor. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93d5ad57-398e-40be-b02c-b2afbe125726"></a><a name="section-5.2.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h3>
<p class="First">Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting their physician (see <a href="#i4i_precautions_id_0c8a7a5f-0d8b-4ab1-ab07-edc8c713a65d">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f54c962-59a9-45ab-8abb-7f70b2b01160"></a><a name="section-5.2.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h3>
<p class="First">Patients should be told to report promptly any indication of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (eg, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) which could be a sign of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p>NOTE: As with many other drugs, certain advice to patients being treated with ACCUPRIL is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_61957d1f-4528-4cd8-b970-69fb6860c06f"></a><a name="section-5.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa30bf39-af55-412a-94ed-618b798287bb"></a><a name="section-5.3.1"></a><p></p>
<h3>Concomitant diuretic therapy</h3>
<p class="First">As with other ACE inhibitors, patients on diuretics, especially those on recently instituted diuretic therapy, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ACCUPRIL. The possibility of hypotensive effects with ACCUPRIL may be minimized by either discontinuing the diuretic or cautiously increasing salt intake prior to initiation of treatment with ACCUPRIL. If it is not possible to discontinue the diuretic, the starting dose of quinapril should be reduced (see <a href="#i4i_dosage_admin_id_520203ca-c42b-4bff-a36c-e84bd7a7d080">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec6c3b07-421a-4229-8d0f-105b4223f586"></a><a name="section-5.3.2"></a><p></p>
<h3>Agents increasing serum potassium</h3>
<p class="First">Quinapril can attenuate potassium loss caused by thiazide diuretics and increase serum potassium when used alone. If concomitant therapy of ACCUPRIL with potassium-sparing diuretics (eg, spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with caution along with appropriate monitoring of serum potassium (see <a href="#i4i_precautions_id_0c8a7a5f-0d8b-4ab1-ab07-edc8c713a65d">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04472863-65a8-4180-b9e3-16182c9dedb6"></a><a name="section-5.3.3"></a><p></p>
<h3>Tetracycline and other drugs that interact with magnesium</h3>
<p class="First">Simultaneous administration of tetracycline with ACCUPRIL reduced the absorption of tetracycline by approximately 28% to 37%, possibly due to the high magnesium content in ACCUPRIL tablets. This interaction should be considered if coprescribing ACCUPRIL and tetracycline or other drugs that interact with magnesium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc83e73b-6902-4bfa-a365-ef7a1cb9517a"></a><a name="section-5.3.4"></a><p></p>
<h3>Lithium</h3>
<p class="First">Increased serum lithium levels and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91ad9a3c-0ed3-4340-ab71-6fe130e2c5f2"></a><a name="section-5.3.5"></a><p></p>
<h3>Gold</h3>
<p class="First">Nitritoid reactions (symptoms include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58bb1832-2d5a-42cf-822a-974fc3cba713"></a><a name="section-5.3.6"></a><p></p>
<h3>Other agents</h3>
<p class="First">Drug interaction studies of ACCUPRIL with other agents showed:</p>
<ul>
<li>Multiple dose therapy with propranolol or cimetidine has no effect on the pharmacokinetics of single doses of ACCUPRIL.</li>
<li>The anticoagulant effect of a single dose of warfarin (measured by <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time) was not significantly changed by quinapril coadministration twice-daily.</li>
<li>ACCUPRIL treatment did not affect the pharmacokinetics of digoxin.</li>
<li>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was observed when single doses of ACCUPRIL and hydrochlorothiazide were administered concomitantly.</li>
<li>Co-administration of multiple 10 mg doses of atorvastatin with 80 mg of ACCUPRIL resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_befb9379-c99f-4395-ac08-5345c5980124"></a><a name="section-5.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Quinapril hydrochloride was not carcinogenic in mice or rats when given in doses up to 75 or 100 mg/kg/day (50 to 60 times the maximum human daily dose, respectively, on an mg/kg basis and 3.8 to 10 times the maximum human daily dose when based on an mg/m<span class="Sup">2</span> basis) for 104 weeks. Female rats given the highest dose level had an increased incidence of mesenteric lymph node <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and skin/subcutaneous <span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipomas</span>. Neither quinapril nor quinaprilat were mutagenic in the Ames bacterial assay with or without metabolic activation. Quinapril was also negative in the following genetic toxicology studies: <span class="Italics">in vitro</span> mammalian cell point mutation, sister chromatid exchange in cultured mammalian cells, micronucleus test with mice, <span class="Italics">in vitro</span> chromosome aberration with V79 cultured lung cells, and in an <span class="Italics">in vivo</span> cytogenetic study with rat bone marrow. There were no adverse effects on fertility or reproduction in rats at doses up to 100 mg/kg/day (60 and 10 times the maximum daily human dose when based on mg/kg and mg/m<span class="Sup">2</span>, respectively).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d3bbfe44-1303-4fda-9bf9-73a8434f47fb"></a><a name="section-5.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Categories C (first trimester) and D (second and third trimesters): See <a href="#i4i_section_id_e2e3f683-87f4-4d30-929a-047e14a063b2">WARNINGS, Fetal/Neonatal Morbidity and Mortality</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_dc17a451-f222-4cd3-87b4-b37b6474a99a"></a><a name="section-5.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because ACCUPRIL is secreted in human milk, caution should be exercised when this drug is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_a66ebb62-ff6c-4421-983e-6fcd55471a5d"></a><a name="section-5.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of ACCUPRIL in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_91470458-2002-4dc4-beab-13ac7a348ea1"></a><a name="section-5.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of ACCUPRIL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
<p>Elderly patients exhibited increased area under the plasma concentration time curve and peak levels for quinaprilat compared to values observed in younger patients; this appeared to relate to decreased renal function rather than to age itself.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_60c22dfc-2d47-4413-affc-028600ab10bb"></a><a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0a89a8f-5732-4657-907d-7616a390f42a"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">ACCUPRIL has been evaluated for safety in 4960 subjects and patients. Of these, 3203 patients, including 655 elderly patients, participated in controlled clinical trials. ACCUPRIL has been evaluated for long-term safety in over 1400 patients treated for 1 year or more. </p>
<p>Adverse experiences were usually mild and transient.</p>
<p>In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 4.7% of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Adverse experiences probably or possibly related to therapy or of unknown relationship to therapy occurring in 1% or more of the 1563 patients in placebo-controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> trials who were treated with ACCUPRIL are shown below.</p>
<a name="id_92e2fedc-5d39-425b-9b2c-88b313cfa65a"></a><table>
<caption><span>Adverse Events in Placebo-Controlled Trials</span></caption>
<col align="left" width="34%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Accupril<br> (N=1563)<br>Incidence<br> (Discontinuance)</td>
<td class="Botrule Lrule" align="left" valign="top">Placebo<br> (N=579)<br>Incidence<br> (Discontinuance)</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Toprule" align="left" valign="top">5.6 (0.7)</td>
<td align="left" valign="top">10.9 (0.7)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left" valign="top">3.9 (0.8)</td>
<td align="left" valign="top">2.6 (0.2)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="left" valign="top">2.6 (0.3)</td>
<td align="left" valign="top">1.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td align="left" valign="top"> 2.0 (0.5)</td>
<td align="left" valign="top">0.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left" valign="top">1.4 (0.3)</td>
<td align="left" valign="top">1.9 (0.2)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="left" valign="top">1.0 (0.2)</td>
<td align="left" valign="top">0.7</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfc74e5e-d63e-4326-80c0-5436aef70be8"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">ACCUPRIL has been evaluated for safety in 1222 ACCUPRIL treated patients. Of these, 632 patients participated in controlled clinical trials. In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 6.8% of patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. </p>
<p>Adverse experiences probably or possibly related or of unknown relationship to therapy occurring in 1% or more of the 585 patients in placebo-controlled <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> trials who were treated with ACCUPRIL are shown below.</p>
<a name="id_ecf04d42-6034-45b2-b66e-262d1b4e1390"></a><table>
<col align="left" width="34%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Accupril<br>(N=585)<br>Incidence<br>(Discontinuance)</td>
<td class="Botrule Lrule" align="left" valign="top">Placebo<br>(N=295)<br>Incidence<br>(Discontinuance)</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Toprule" align="left" valign="top">7.7 (0.7)</td>
<td align="left" valign="top">5.1 (1.0)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td align="left" valign="top">4.3 (0.3)</td>
<td align="left" valign="top">1.4<br>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="left" valign="top">2.6 (0.2)</td>
<td align="left" valign="top">1.4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left" valign="top">2.4 (0.2)</td>
<td align="left" valign="top">0.7</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td align="left" valign="top">2.4</td>
<td align="left" valign="top">1.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td align="left" valign="top">2.9 (0.5)</td>
<td align="left" valign="top">1.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="left" valign="top">1.9 (0.2)</td>
<td align="left" valign="top">2.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left" valign="top">1.7</td>
<td align="left" valign="top">1.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left" valign="top">1.7</td>
<td align="left" valign="top">1.0 (0.3)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="left" valign="top">1.5</td>
<td align="left" valign="top">2.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="left" valign="top">1.4 (0.2)</td>
<td align="left" valign="top">1.0</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="left" valign="top">1.2</td>
<td align="left" valign="top">0.3</td>
</tr>
</tbody>
</table>
<p>See <a href="#i4i_section_id_24da3877-24b8-4635-988f-076bfd82f17c">PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4b68ec6-1764-4aa5-b093-b3b7f459b168"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and/or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">Clinical adverse experiences probably, possibly, or definitely related, or of uncertain relationship to therapy occurring in 0.5% to 1.0% (except as noted) of the patients with CHF or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> treated with ACCUPRIL (with or without concomitant diuretic) in controlled or uncontrolled trials (N=4847) and less frequent, clinically significant events seen in clinical trials or post-marketing experience (the rarer events are in italics) include (listed by body system):</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span></span></p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, vasodilation, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, cardiac rhythm disturbances, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> </span></p>
<p><span class="Bold">Hematology:</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></span></p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> or throat, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> </span></p>
<p><span class="Bold">Nervous/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p>
<p><span class="Bold">Integumentary:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, dermatopolymyositis</span></p>
<p><span class="Bold">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, worsening <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></span></p>
<p><span class="Bold">Respiratory:</span> <span class="Italics">eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span></span></p>
<p><span class="Bold">Other:</span> <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d4f1d3aa-a5d5-4809-9d07-e77850e13770"></a><a name="section-6.4"></a><p></p>
<h2>Fetal/Neonatal Morbidity and Mortality</h2>
<p class="First"><span class="Bold">See <a href="#i4i_section_id_e2e3f683-87f4-4d30-929a-047e14a063b2">WARNINGS, Fetal/Neonatal Morbidity and Mortality</a>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_693b6b8f-da69-497e-b92f-8f9ab223928b"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> has been reported in patients receiving ACCUPRIL (0.1%). <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> may be fatal. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of the face, extremities, lips, tongue, glottis, and/or larynx occurs, treatment with ACCUPRIL should be discontinued and appropriate therapy instituted immediately. (See <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a94b3e6-2218-4ea8-8c43-0f42ecea2def"></a><a name="section-6.4.2"></a><p></p>
<h3>Clinical Laboratory Test Findings</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d912029a-6899-49a3-92af-fe0340c52ca4"></a><a name="section-6.4.2.1"></a><p></p>
<h4>Hematology</h4>
<p class="First">(See <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fbccb41c-4e06-4f4e-ae1a-6c729944f5c1"></a><a name="section-6.4.2.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h4>
<p class="First">(See <a href="#i4i_precautions_id_0c8a7a5f-0d8b-4ab1-ab07-edc8c713a65d">PRECAUTIONS</a>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c59f264-1d04-4100-9aef-6c12a122ea19"></a><a name="section-6.4.2.3"></a><p></p>
<h4>Creatinine and Blood Urea Nitrogen</h4>
<p class="First">Increases (&gt;1.25 times the upper limit of normal) in serum creatinine and blood urea nitrogen were observed in 2% and 2%, respectively, of all patients treated with ACCUPRIL alone. Increases are more likely to occur in patients receiving concomitant diuretic therapy than in those on ACCUPRIL alone. These increases often remit on continued therapy. In controlled studies of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, increases in blood urea nitrogen and serum creatinine were observed in 11% and 8%, respectively, of patients treated with ACCUPRIL; most often these patients were receiving diuretics with or without digitalis.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_0604fb6d-04ae-4394-b56f-ebf968cb7b1e"></a><a name="section-7"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Doses of 1440 to 4280 mg/kg of quinapril cause significant lethality in mice and rats.</p>
<p>No specific information is available on the treatment of overdosage with quinapril. The most likely clinical manifestation would be symptoms attributable to severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>Laboratory determinations of serum levels of quinapril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of quinapril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>No data are available to suggest physiological maneuvers (eg, maneuvers to change pH of the urine) that might accelerate elimination of quinapril and its metabolites.</p>
<p>Hemodialysis and peritoneal dialysis have little effect on the elimination of quinapril and quinaprilat. Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of quinapril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, but angiotensin II is essentially unavailable outside of scattered research facilities. Because the hypotensive effect of quinapril is achieved through vasodilation and effective <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, it is reasonable to treat quinapril <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> by infusion of normal saline solution.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_520203ca-c42b-4bff-a36c-e84bd7a7d080"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9d352c1-1d39-4815-b989-950c515f571b"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b02ca4b-cd89-4fab-b7dd-2cbc40c13138"></a><a name="section-8.1.1"></a><p></p>
<h3>Monotherapy</h3>
<p class="First">The recommended initial dosage of ACCUPRIL in patients not on diuretics is 10 or 20 mg once daily. Dosage should be adjusted according to blood pressure response measured at peak (2–6 hours after dosing) and trough (predosing). Generally, dosage adjustments should be made at intervals of at least 2 weeks. Most patients have required dosages of 20, 40, or 80 mg/day, given as a single dose or in two equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients an increase in dosage or twice daily administration may be warranted. In general, doses of 40–80 mg and divided doses give a somewhat greater effect at the end of the dosing interval.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f78300ff-3f93-4468-a09a-383c60ecf0fb"></a><a name="section-8.1.2"></a><p></p>
<h3>Concomitant Diuretics</h3>
<p class="First">If blood pressure is not adequately controlled with ACCUPRIL monotherapy, a diuretic may be added. In patients who are currently being treated with a diuretic, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occasionally can occur following the initial dose of ACCUPRIL. To reduce the likelihood of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, the diuretic should, if possible, be discontinued 2 to 3 days prior to beginning therapy with ACCUPRIL (see <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>). Then, if blood pressure is not controlled with ACCUPRIL alone, diuretic therapy should be resumed.</p>
<p>If the diuretic cannot be discontinued, an initial dose of 5 mg ACCUPRIL should be used with careful medical supervision for several hours and until blood pressure has stabilized.</p>
<p>The dosage should subsequently be titrated (as described above) to the optimal response (see <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>, <a href="#i4i_precautions_id_0c8a7a5f-0d8b-4ab1-ab07-edc8c713a65d">PRECAUTIONS</a>, and <a href="#i4i_interactions_id_61957d1f-4528-4cd8-b970-69fb6860c06f">Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c3c3279-b0c8-42c9-8349-123863147636"></a><a name="section-8.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">Kinetic data indicate that the apparent elimination half-life of quinaprilat increases as creatinine clearance decreases. Recommended starting doses, based on clinical and pharmacokinetic data from patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, are as follows:</p>
<a name="id_4b6e4313-545c-488e-ae5d-9f734b8b0270"></a><table>
<col align="left" width="50%">
<col align="center" width="50%">
<thead><tr class="Botrule First Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Creatinine<br>Clearance</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Maximum Recommended<br>Initial Dose</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">&gt;60 mL/min</td>
<td class="Rrule" align="left" valign="top">10 mg</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">30–60 mL/min</td>
<td class="Rrule" align="left" valign="top">5 mg</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">10–30 mL/min</td>
<td class="Rrule" align="left" valign="top"> 2.5 mg</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">&lt;10 mL/min</td>
<td class="Rrule" align="left" valign="top">Insufficient data for dosage recommendation</td>
</tr>
</tbody>
</table>
<p>Patients should subsequently have their dosage titrated (as described above) to the optimal response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_610b643a-b80c-4dc6-aa1e-c036b958fafc"></a><a name="section-8.1.4"></a><p></p>
<h3>Elderly (≥65 years)</h3>
<p class="First">The recommended initial dosage of ACCUPRIL in elderly patients is 10 mg given once daily followed by titration (as described above) to the optimal response.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_70335ff9-4b00-4219-b17e-bd14a06bfac1"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">ACCUPRIL is indicated as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis. The recommended starting dose is 5 mg twice daily. This dose may improve symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, but increases in exercise duration have generally required higher doses. Therefore, if the initial dosage of ACCUPRIL is well tolerated, patients should then be titrated at weekly intervals until an effective dose, usually 20 to 40 mg daily given in two equally divided doses, is reached or undesirable <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, orthostatis, or <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> (see <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>) prohibit reaching this dose. </p>
<p>Following the initial dose of ACCUPRIL, the patient should be observed under medical supervision for at least two hours for the presence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or orthostatis and, if present, until blood pressure stabilizes. The appearance of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, orthostatis, or <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> early in dose titration should not preclude further careful dose titration. Consideration should be given to reducing the dose of concomitant diuretics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_19b85c77-b623-4542-a8a4-da1c78a77f46"></a><a name="section-8.3"></a><p></p>
<h2>DOSE ADJUSTMENTS IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> AND <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">RENAL IMPAIRMENT</span> OR <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">HYPONATREMIA</span></h2>
<p class="First">Pharmacokinetic data indicate that quinapril elimination is dependent on level of renal function. In patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the recommended initial dose of ACCUPRIL is 5 mg in patients with a creatinine clearance above 30 mL/min and 2.5 mg in patients with a creatinine clearance of 10 to 30 mL/min. There is insufficient data for dosage recommendation in patients with a creatinine clearance less than 10 mL/min (see <a href="#i4i_section_id_70335ff9-4b00-4219-b17e-bd14a06bfac1">DOSAGE AND ADMINISTRATION, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a>, <a href="#i4i_warnings_id_6c815fe3-a206-484d-a321-5104f7792813">WARNINGS</a>, and <a href="#i4i_interactions_id_61957d1f-4528-4cd8-b970-69fb6860c06f">PRECAUTIONS, Drug Interactions</a>).</p>
<p>If the initial dose is well tolerated, ACCUPRIL may be administered the following day as a twice daily regimen. In the absence of excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or significant deterioration of renal function, the dose may be increased at weekly intervals based on clinical and hemodynamic response.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_157f5329-11b3-4c9d-9536-2cb2b60ca26e"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ACCUPRIL tablets are supplied as follows:</p>
<p><span class="Bold">5-mg tablets:</span> brown, film-coated, elliptical scored tablets, coded "PD 527" on one side and "5" on the other.</p>
<p> N0071-0527-23 bottles of 90 tablets<br>N0071-0527-40 10 × 10 unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></p>
<p><span class="Bold">10-mg tablets:</span> brown, film-coated, triangular tablets, coded "PD 530" on one side and "10" on the other.</p>
<p>N0071-0530-23 bottles of 90 tablets<br>N0071-0530-40 10 × 10 unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></p>
<p><span class="Bold">20-mg tablets:</span> brown, film-coated, round tablets, coded "PD 532" on one side and "20" on the other.</p>
<p>N0071-0532-23 bottles of 90 tablets<br>N0071-0532-40 10 × 10 unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></p>
<p><span class="Bold">40-mg tablets:</span> brown, film-coated, elliptical tablets, coded "PD 535" on one side and "40" on the other.</p>
<p>N0071-0535-23 bottles of 90 tablets</p>
<p>Dispense in well-closed containers as defined in the USP.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_cdc11fbf-8765-47be-88a4-91a51b3ae0a6"></a><a name="section-9.1"></a><p></p>
<h2>Storage</h2>
<p class="First"><span class="Bold">Store at controlled room temperature 15º–30ºC (59º–86ºF).</span></p>
<p><span class="Bold">Protect from light.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3df2891b-5659-40b4-b2a5-80632e1eb6b5"></a><a name="section-10"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a2de05b9-d1aa-4fbb-a9a3-6918cc306f78&amp;name=b342078c-2f2f-4f66-82bd-1ac0c095fbc1-02.jpg"></p>
<p>LAB-0215-5.0</p>
<p>April 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_9c70e2c9-823b-46c1-b09c-f985b6555ad8"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC: 55154-2418-0</p>
<p>Accupril<span class="Sup">®</span></p>
<p>10 mg*</p>
<p>Quinapril HCl Tablets</p>
<p>10 Tablets</p>
<div class="Figure"><img alt="Bag Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a2de05b9-d1aa-4fbb-a9a3-6918cc306f78&amp;name=b342078c-2f2f-4f66-82bd-1ac0c095fbc1-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0d5ef61a-9da2-4b5a-a1c7-e630310523bc"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC: 55154-2423-0</p>
<p>Accupril<span class="Sup">®</span></p>
<p>20 mg*</p>
<p>Quinapril HCl Tablets</p>
<p>10 Tablets</p>
<div class="Figure"><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a2de05b9-d1aa-4fbb-a9a3-6918cc306f78&amp;name=b342078c-2f2f-4f66-82bd-1ac0c095fbc1-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACCUPRIL 		
					</strong><br><span class="contentTableReg">quinapril hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-2418(NDC:0071-0530)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>QUINAPRIL HYDROCHLORIDE</strong> (QUINAPRILAT) </td>
<td class="formItem">QUINAPRIL</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>candelilla wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium carbonate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PD;530;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2418-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019885</td>
<td class="formItem">11/19/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACCUPRIL 		
					</strong><br><span class="contentTableReg">quinapril hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-2423(NDC:0071-0532)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>QUINAPRIL HYDROCHLORIDE</strong> (QUINAPRILAT) </td>
<td class="formItem">QUINAPRIL</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>candelilla wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium carbonate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PD;532;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2423-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019885</td>
<td class="formItem">11/19/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-2418, 55154-2423)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b342078c-2f2f-4f66-82bd-1ac0c095fbc1</div>
<div>Set id: a2de05b9-d1aa-4fbb-a9a3-6918cc306f78</div>
<div>Version: 2</div>
<div>Effective Time: 20130409</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
